Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.

Next Previous
X
Search
Trial Profile

A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golnerminogene pradenovec (Primary) ; Fluorouracil; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms PACT
  • Sponsors GenVec

    • Most Recent Events

    • 22 Jan 2013 Final results published in the Journal of Clinical Oncology.
    • 04 Jun 2012 Primary endpoint 'Overall-survival' has not been met.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top